Infectious Diseases in Obstetrics and Gynecology / 2018 / Article / Tab 6

Research Article

Universal Rapid Human Immunodeficiency Virus Screening at Delivery: A Cost-Effectiveness Analysis

Table 6

Univariate sensitivity analysis of universal rapid HIV screening relative to standard of care II.

VariableDetected rangeEstimated incremental cost ($)Estimated incremental QALY (10−5)Incremental cost-effectiveness ratio ($/QALY)

QALY saved per prevention of 1 case of MTCT5~2526,968.761.97~9.8313,720.22~2,744.04
Estimated lifetime medical cost of PAH$250k~550k53,759.00~(−64,178.29)7.477,197.27~(−8,592.20)
HIV prevalence0.5%~10%27,353.64~24,741.987.58~6.853,610.58~3,610.58
HIV annual cumulative incidence0.01%~0.15%136,311.47~(−62,625.81)0.86~12.89158,710.06~(−4,860.01)
Cost of rapid test$11.90~$16.32(−2,660.25)~39,859.317.47(−356.16)~5,336.37
Cost of neonatal prophylaxis$185~$21026,968.76~27,267.687.473,610.58~3,650.60

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.